Back to Search
Start Over
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing
- Source :
- Relling , M V , Gardner , E E , Sandborn , W J , Schmiegelow , K , Pui , C-H , Yee , S W , Stein , P C , Carrillo , M B , Evans , W E , Klein , T E & Clinical Pharmacogenetics Implementation Consortium 2011 , ' Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing ' , Clinical Pharmacology and Therapeutics , vol. 89 , no. 3 , pp. 387-91 .
- Publication Year :
- 2011
-
Abstract
- Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.
Details
- Database :
- OAIster
- Journal :
- Relling , M V , Gardner , E E , Sandborn , W J , Schmiegelow , K , Pui , C-H , Yee , S W , Stein , P C , Carrillo , M B , Evans , W E , Klein , T E & Clinical Pharmacogenetics Implementation Consortium 2011 , ' Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing ' , Clinical Pharmacology and Therapeutics , vol. 89 , no. 3 , pp. 387-91 .
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1408248433
- Document Type :
- Electronic Resource